Anixa Biosciences, Inc. (ANIX)Healthcare | Biotechnology | San Jose, United States | NasdaqCM
3.48 USD
-0.12
(-3.333%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 3.70 +0.22 (6.322%) ⇧ (Aug. 28, 2026, 7:51 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 4:22 a.m. EDT
The long-term outlook is severely compromised by a four-year streak of declining annual returns, which serves as direct evidence of structural deterioration in the business despite the company's patent portfolio expansion. While the balance sheet remains robust with negligible debt and massive liquidity, the market has already priced out the growth story, reflected in the persistent multi-year price decline. The short-term picture is mixed; while insider buying and a recent price bounce suggest some optimism, the statistical forecast offers no directional edge, and options flow indicates a bearish bias with heavy protection bought at higher strikes. Without a confirmed turnaround in the annual growth trajectory, this remains a speculative hold rather than a conviction investment. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.170517 |
| AutoTheta | 0.170554 |
| AutoETS | 0.320741 |
| MSTL | 0.342598 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 24.68 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.160 |
| Excess Kurtosis | -1.31 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.391 |
| Market Cap | 118,400,264 |
| Forward P/E | -11.23 |
| Beta | 0.52 |
| Website | https://www.anixa.com |
As of Aug. 22, 2026, 4:22 a.m. EDT: Speculators are positioning for a significant downside move, evidenced by heavy put open interest at the $7.50 strike for October expiration compared to minimal call activity. Conversely, there is a distinct 'pin risk' buildup at the $5.00 strike across multiple expirations, suggesting traders expect the stock to stall or reverse near that level rather than break through it immediately.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.12621355 |
| Address1 | 3,150 Almaden Expressway |
| Address2 | Suite 250 |
| All Time High | 259.375 |
| All Time Low | 0.6 |
| Ask | 4.37 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 294,310 |
| Average Daily Volume3 Month | 255,073 |
| Average Volume | 255,073 |
| Average Volume10Days | 294,310 |
| Beta | 0.524 |
| Bid | 2.57 |
| Bid Size | 2 |
| Book Value | 0.427 |
| City | San Jose |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.48 |
| Current Ratio | 9.788 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 3.67 |
| Day Low | 3.42 |
| Debt To Equity | 1.391 |
| Display Name | Anixa Biosciences |
| Earnings Timestamp | 1,788,984,000 |
| Earnings Timestamp End | 1,788,984,000 |
| Earnings Timestamp Start | 1,788,984,000 |
| Ebitda Margins | 0.0 |
| Enterprise Value | 103,647,256 |
| Eps Current Year | -0.31 |
| Eps Forward | -0.31 |
| Eps Trailing Twelve Months | -0.29 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.3002 |
| Fifty Day Average Change | 0.17980003 |
| Fifty Day Average Change Percent | 0.05448156 |
| Fifty Two Week Change Percent | 12.621355 |
| Fifty Two Week High | 5.46 |
| Fifty Two Week High Change | -1.98 |
| Fifty Two Week High Change Percent | -0.36263737 |
| Fifty Two Week Low | 2.32 |
| Fifty Two Week Low Change | 1.1600001 |
| Fifty Two Week Low Change Percent | 0.50000006 |
| Fifty Two Week Range | 2.32 - 5.46 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 434,381,400,000 |
| Float Shares | 32,153,496 |
| Forward Eps | -0.31 |
| Forward P E | -11.225806 |
| Free Cashflow | -3,635,875 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 4 |
| Fullday Change | -0.12 |
| Fullday Change Percent | -3.33333 |
| Fullday Price | 3.7 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.05495 |
| Held Percent Institutions | 0.14155 |
| Implied Shares Outstanding | 34,023,063 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,761,868,800 |
| Last Split Date | 1,435,276,800 |
| Last Split Factor | 1:25 |
| Long Business Summary | Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast cancer; and the development of a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California. |
| Long Name | Anixa Biosciences, Inc. |
| Market | us_market |
| Market Cap | 118,400,264 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_263802 |
| Most Recent Quarter | 1,777,507,200 |
| Net Income To Common | -10,034,000 |
| Next Fiscal Year End | 1,793,404,800 |
| Non Diluted Market Cap | 122,142,796 |
| Number Of Analyst Opinions | 4 |
| Open | 3.6 |
| Operating Cashflow | -7,117,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Peg Ratio | -0.11 |
| Phone | 408 708 9808 |
| Post Market Change | 0.22000003 |
| Post Market Change Percent | 6.3218403 |
| Post Market Price | 3.7 |
| Post Market Time | 1,787,961,114 |
| Previous Close | 3.6 |
| Price Eps Current Year | -11.225806 |
| Price Hint | 4 |
| Price To Book | 8.149883 |
| Profit Margins | 0.0 |
| Quick Ratio | 9.155 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.12 |
| Regular Market Change Percent | -3.33333 |
| Regular Market Day High | 3.67 |
| Regular Market Day Low | 3.42 |
| Regular Market Day Range | 3.42 - 3.67 |
| Regular Market Open | 3.6 |
| Regular Market Previous Close | 3.6 |
| Regular Market Price | 3.48 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 214,684 |
| Return On Assets | -0.41906 |
| Return On Equity | -0.71973 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 34,023,063 |
| Shares Percent Shares Out | 0.0287 |
| Shares Short | 977,973 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 862,186 |
| Short Name | Anixa Biosciences, Inc. |
| Short Percent Of Float | 0.030299999 |
| Short Ratio | 4.01 |
| Source Interval | 15 |
| State | CA |
| Symbol | ANIX |
| Target High Price | 14.0 |
| Target Low Price | 7.0 |
| Target Mean Price | 10.0 |
| Target Median Price | 9.5 |
| Total Cash | 13,686,000 |
| Total Cash Per Share | 0.402 |
| Total Debt | 184,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.29 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.1936 |
| Two Hundred Day Average Change | 0.28640008 |
| Two Hundred Day Average Change Percent | 0.08967938 |
| Type Disp | Equity |
| Volume | 214,684 |
| Website | https://www.anixa.com |
| Zip | 95,118 |